Abstract:Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating physicians, approximately one‐third of patients with ATTRwt‐CM are initially misdiagnosed with other cardiac diseases. Although heart failure (HF) is the most common initial manifestation of ATTRwt‐CM, observed in nearly 70% of affected patients, patients may also present with other cardiologic symptoms, such as atrial fibrillation (AF) and aortic stenosis (AS). This non‐specific and diverse nature of the initial ATTRwt‐CM presentation indicates that various cardiology subspecialties are involved in patient diagnosis and management. Standard guideline‐directed pharmacological treatment for HF is not recommended for patients with ATTRwt‐CM because of its limited effectiveness. However, no established algorithms are available regarding HF management in this patient population. This literature review provides an overview of the red flags for ATTRwt‐CM and research findings regarding HF management in this patient population. In addition to commonly recognized red flags for ATTRwt‐CM (e.g., HF, AF and severe AS), published literature identified potential red flags such as coronary microvascular dysfunction. For HF management in patients with ATTRwt‐CM, the use of mineralocorticoid receptor antagonists (MRAs) was reported as a well‐tolerated option associated with a low discontinuation rate and reduced mortality. Although there is no concrete evidence for recommendations against sodium‐glucose cotransporter 2 inhibitor (SGLT2i) administration, research supporting its use is limited to small‐scale studies. Robust evidence is lacking for AF ablation, implantable cardioverter‐defibrillators and cardiac resynchronization therapy. Based on the published findings and our clinical experience as Japanese ATTRwt‐CM experts, red‐flag symptom clusters for each cardiology specialty (HF, arrhythmia and ischaemia/structural heart disease) and a treatment scheme for HF management are presented. As this research area remains at an exploratory stage, our observations would require further discussion among experts worldwide.

Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy

Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis

Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review

Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis

Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond

Treatment of transthyretin cardiac amyloidosis

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

Prevalence of transthyretin amyloid cardiomyopathy in patients admitted for acute heart failure

Disease-modifying treatments in transthyretin amyloid cardiomyopathy: a meta-analysis of randomized controlled trials

Therapy of ATTR Cardiac Amyloidosis: Current Indications

Treatment of cardiac transthyretin amyloidosis: an update

Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years

Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis

Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness

Clinical Characteristics and Prognosis of Chinese Patients with Hereditary Transthyretin Amyloid Cardiomyopathy

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries

Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment